α-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden.
Levin J, Baiardi S, Quadalti C, Rossi M, Mammana A, Vöglein J, Bernhardt A, Perrin RJ, Jucker M, Preische O, Hofmann A, Höglinger GU, Cairns NJ, Franklin EE, Chrem P, Cruchaga C, Berman SB, Chhatwal JP, Daniels A, Day GS, Ryan NS, Goate AM, Gordon BA, Huey ED, Ibanez L, Karch CM, Lee JH, Llibre-Guerra J, Lopera F, Masters CL, Morris JC, Noble JM, Renton AE, Roh JH, Frosch MP, Keene CD, McLean C, Sanchez-Valle R, Schofield PR, Supnet-Bell C, Xiong C, Giese A, Hansson O, Bateman RJ, McDade E; Dominantly Inherited Alzheimer Network; Parchi P.
Levin J, et al.
Alzheimers Dement. 2024 Apr 26. doi: 10.1002/alz.13818. Online ahead of print.
Alzheimers Dement. 2024.
PMID: 38666355
However, Lewy body pathology (LBP) is found in 50% of AD and ADAD brains. METHODS: Using an alpha-synuclein seed amplification assay (SAA) in cerebrospinal fluid (CSF) from asymptomatic (n = 26) and symptomatic (n = 27) ADAD mutation carriers, including 12 with known neuro …
However, Lewy body pathology (LBP) is found in 50% of AD and ADAD brains. METHODS: Using an alpha-synuclein seed amplification assay (SAA …